Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company'…
An institutional-grade, numbers-driven thesis on VRDN — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 16, 2026, TradersQuant's model rates Viridian Therapeutics, Inc. (VRDN) 69/100 with a 12-month base-case forecast of $37.25 — +68.7% versus the current price of $22.08. Viridian Therapeutics, Inc. trades at $22.08 in the Healthcare sector, with a market capitalisation of $2.50B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for VRDN is $37.25, implying +68.7% versus the current price. The model's 12-month scenario range runs from $26.80 (bear) to $34.49 (bull), with a base case of $29.28.
On the fundamentals, Viridian Therapeutics shows a P/E of -6.3, trailing revenue of $70.8M, revenue growth of +23359.9% YoY. This page also tracks VRDN's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
VRDN currently carries a TradersQuant composite score of 69/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $37.25 implies +68.7% from $22.08. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for VRDN is $37.25, about +68.7% versus the latest price of $22.08. Consensus is based on 16 analysts.
TradersQuant's 12-month model forecast for VRDN is a base case of $29.28, ranging from $26.80 (bear) to $34.49 (bull), an expected return of +32.6%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for VRDN over the next 12 months is $29.28 in the base case (bear $26.80, bull $34.49), versus today's price of $22.08. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for VRDN — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates VRDN's fair value at $37.25, implying +68.7% of expected upside versus the current price.
Viridian Therapeutics does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
